← Leaderboards
Paul D Griffiths
University College London
$865,817
Attributed
$865,817
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $303.3K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$865,817 · 1
By mechanism
R01$865,817 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Trial Phase I”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$674,722,986
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$549,289,302
- Barton F Haynes · Duke University$532,133,792
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$407,280,377
Research focus
Clinical Trial Phase IHerpesviridae VaccineNeutralizing AntibodyCytomegalovirusGlycoproteinsPatient Oriented ResearchClinical ResearchLongitudinal Human StudyVirus ProteinVirus LoadTransplantation ImmunologyHuman SubjectActive ImmunizationHuman Therapy EvaluationAntibody TiteringDosageCytomegalovirus VaccinesCytomegalovirus InfectionsCaringGeneticCmv Glycoprotein BAdjuvantGenesGanciclovir
Grant awards (5)
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE$303,258
R01 · FY2008 · AI · contact PI
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE$184,559
R01 · FY2006 · AI · contact PI
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE$188,999
R01 · FY2005 · AI
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE$1
R01 · FY2004 · AI
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE$189,000
R01 · FY2003 · AI